Impact of acute kidney injury response on survival and liver transplant rates in hospitalized patients with cirrhosis awaiting liver transplantation: Results from the HRS-HARMONY consortium.


Journal

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
ISSN: 1527-6473
Titre abrégé: Liver Transpl
Pays: United States
ID NLM: 100909185

Informations de publication

Date de publication:
30 Jul 2024
Historique:
received: 02 06 2024
accepted: 06 06 2024
medline: 29 7 2024
pubmed: 29 7 2024
entrez: 29 7 2024
Statut: aheadofprint

Résumé

Acute kidney injury (AKI) frequently complicates the course of hospitalized patients with cirrhosis and negatively affects their prognosis. How AKI response influences the timing of liver transplantation (LT) remains unclear. We sought to assess the impact of AKI response to treatment on survival and LT rates in cirrhosis patients awaiting LT. This was a retrospective multicenter study of cirrhosis patients waitlisted for LT and hospitalized with AKI in 2019. The exposure was AKI response versus no response during hospitalization. Outcomes were 90-day overall and transplant-free survival, and rates of LT with time to transplant. We adjusted for age, sex, race, cirrhosis etiology, site, and MELD-Na score. Among the 317 patients in this study, 170 had AKI response (53.6%), and 147 had no response (46.4%). Compared to non-responders, responders had better 90-day overall survival (89.4% vs. 76.2%, adjusted sHR for mortality 0.34, p=0.001), and transplant-free survival (63.5% vs. 25.2%, aHR for probability of death or transplant 0.35, p<0.001). The LT rate was lower in responders (45.9% vs. 61.2%, adjusted sHR 0.55, p=0.005). 79% of transplants in responders occurred after discharge, at a median of 103 days, while 62% of transplants in non-responders occurred during hospitalization, with the remainder occurring post-discharge at a median of 58 days. In patients with cirrhosis waitlisted for LT who are hospitalized with AKI, AKI response to therapy is associated with improved 90-day survival, despite a reduced LT rate and longer time to LT.

Sections du résumé

BACKGROUND & AIMS OBJECTIVE
Acute kidney injury (AKI) frequently complicates the course of hospitalized patients with cirrhosis and negatively affects their prognosis. How AKI response influences the timing of liver transplantation (LT) remains unclear. We sought to assess the impact of AKI response to treatment on survival and LT rates in cirrhosis patients awaiting LT.
APPROACH & RESULTS RESULTS
This was a retrospective multicenter study of cirrhosis patients waitlisted for LT and hospitalized with AKI in 2019. The exposure was AKI response versus no response during hospitalization. Outcomes were 90-day overall and transplant-free survival, and rates of LT with time to transplant. We adjusted for age, sex, race, cirrhosis etiology, site, and MELD-Na score. Among the 317 patients in this study, 170 had AKI response (53.6%), and 147 had no response (46.4%). Compared to non-responders, responders had better 90-day overall survival (89.4% vs. 76.2%, adjusted sHR for mortality 0.34, p=0.001), and transplant-free survival (63.5% vs. 25.2%, aHR for probability of death or transplant 0.35, p<0.001). The LT rate was lower in responders (45.9% vs. 61.2%, adjusted sHR 0.55, p=0.005). 79% of transplants in responders occurred after discharge, at a median of 103 days, while 62% of transplants in non-responders occurred during hospitalization, with the remainder occurring post-discharge at a median of 58 days.
CONCLUSIONS CONCLUSIONS
In patients with cirrhosis waitlisted for LT who are hospitalized with AKI, AKI response to therapy is associated with improved 90-day survival, despite a reduced LT rate and longer time to LT.

Identifiants

pubmed: 39073567
doi: 10.1097/LVT.0000000000000445
pii: 01445473-990000000-00425
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Association for the Study of Liver Diseases.

Auteurs

Xing Li (X)

Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA.

Tianqi Ouyang (T)

Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA.

Justin M Belcher (JM)

Section of Nephrology, Department of Internal Medicine, Yale University and VA Connecticut Healthcare, New Haven, CT.

Kavish R Patidar (KR)

Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX.

Giuseppe Cullaro (G)

Division of Gastroenterology, University of California, San Francisco, CA.

Sumeet K Asrani (SK)

Baylor University Medical Center, Dallas, TX.

Hani Wadei (H)

Department of Transplantation, Mayo Clinic, Jacksonville, FL.

Douglas A Simonetto (DA)

Division of Gastroenterology and Transplant Hepatology, Mayo Clinic, Rochester, Rochester, MN.

Kevin R Regner (KR)

Division of Nephrology at the Medical College of Wisconsin, Milwaukee, WI.

Leigh A Dageforde (LA)

Department of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA.

Eric M Przybyszewski (EM)

Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA.

Robert M Wilechansky (RM)

Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA.

Pratima Sharma (P)

Department of Gastroenterology and Transplant Hepatology at University of Michigan Health, Ann Arbor, MI.

Nneka N Ufere (NN)

Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA.

Andres Duarte-Rojo (A)

Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern University, Chicago, IL.

Nabeel A Wahid (NA)

Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern University, Chicago, IL.

Eric S Orman (ES)

Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX.

Shelsea A St Hillien (SA)

Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA.

Jevon E Robinson (JE)

Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA.

Raymond T Chung (RT)

Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA.

Andrew S Allegretti (AS)

Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA.

Classifications MeSH